FY2025 Earnings Forecast for XOMA Issued By Leerink Partnrs

XOMA Co. (NASDAQ:XOMA - Free Report) - Research analysts at Leerink Partnrs raised their FY2025 earnings per share (EPS) estimates for XOMA in a research report issued on Tuesday, March 18th. Leerink Partnrs analyst D. Risinger now anticipates that the biotechnology company will earn ($0.60) per share for the year, up from their prior forecast of ($0.97). The consensus estimate for XOMA's current full-year earnings is ($1.41) per share. Leerink Partnrs also issued estimates for XOMA's FY2026 earnings at $0.53 EPS, FY2027 earnings at $2.54 EPS and FY2028 earnings at $5.81 EPS.

Several other equities research analysts have also recently weighed in on XOMA. HC Wainwright restated a "buy" rating and set a $104.00 target price on shares of XOMA in a research note on Wednesday, March 19th. StockNews.com raised XOMA from a "sell" rating to a "hold" rating in a research note on Friday.

XOMA Price Performance

Shares of XOMA stock traded up $0.05 on Thursday, reaching $20.93. 35,063 shares of the stock were exchanged, compared to its average volume of 26,515. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52. The firm has a market cap of $250.72 million, a PE ratio of -6.01 and a beta of 1.00. The firm's 50 day moving average is $24.28 and its 200-day moving average is $27.08. XOMA has a one year low of $19.92 and a one year high of $35.00.

Remove Ads

XOMA (NASDAQ:XOMA - Get Free Report) last posted its quarterly earnings data on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.17). XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. The firm had revenue of $8.70 million for the quarter, compared to the consensus estimate of $8.75 million.

Insider Activity

In other news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the firm's stock in a transaction on Friday, January 24th. The shares were sold at an average price of $26.10, for a total transaction of $13,069,366.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 7.20% of the stock is owned by corporate insiders.

Institutional Trading of XOMA

Institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC grew its position in shares of XOMA by 0.6% in the 3rd quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company's stock valued at $4,840,000 after buying an additional 1,138 shares during the last quarter. Barclays PLC boosted its holdings in XOMA by 300.7% in the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company's stock valued at $298,000 after acquiring an additional 8,447 shares during the last quarter. BNP Paribas Financial Markets increased its position in XOMA by 95.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company's stock valued at $43,000 after purchasing an additional 795 shares during the period. State Street Corp raised its holdings in XOMA by 1.2% during the 3rd quarter. State Street Corp now owns 142,857 shares of the biotechnology company's stock worth $3,783,000 after purchasing an additional 1,754 shares during the last quarter. Finally, New York State Common Retirement Fund lifted its position in shares of XOMA by 51.2% in the 4th quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company's stock worth $62,000 after purchasing an additional 800 shares during the period. 95.92% of the stock is currently owned by institutional investors and hedge funds.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.